Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 11:43 PM
Ignite Modification Date:
2025-12-24 @ 11:43 PM
NCT ID:
NCT02331251
Brief Summary:
The Phase Ib and II cohorts will enroll patients with metistatic solid tumors.
Phase II only will enroll the following patients:
Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine, pembro plus gemcitabine and docetaxel, pembro plus gemcitabine and vinorelbine, and pembro plus liposomal doxorubicin.
Patients with metastatic pancreatic adenocarcinoma to be enrolled in the pembro plus gemcitabine and nab-paclitaxel arm.
Patients with extensive-stage small cell lung cancer to be enrolled in the pembro plus irinotecan arm.
Patients with ER+ breast cancer to be enrolled in the pembro and vinorelbine arm.
Patients with ovarian cancer to be enrolled in the pembroplus liposomal doxorubicin arm.
Patients with metastatic TNBC (ER/PR/HER2 negative) to be enrolled in the pembro plus gemcitabine arm.
Detailed Description:
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks.
Study:
NCT02331251
Study Brief:
Protocol Section:
NCT02331251